Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

I agree, but though the IBD/Crohn's/ulcerative colitis market is huge, it remains so far away without prying a few bucks out of an OM or an ABSSSI treatment sale/licensing. This lack of movement even affects the potential of Kevetrin (which may or may not be huge, as we all know). But would be nice to find out. The constant putting all off into the future is strange. And as time ticks off, potential competitors in every area progress.